🇺🇸 VOQUEZNA® Triple Pak® in United States

FDA authorised VOQUEZNA® Triple Pak® on 3 May 2022

Marketing authorisation

FDA — authorised 3 May 2022

  • Application: NDA215152
  • Marketing authorisation holder: PHATHOM
  • Local brand name: VOQUEZNA TRIPLE PAK
  • Indication: CAPSULE, TABLET, TABLET — ORAL
  • Status: approved

Read official source →

Other Gastroenterology / Infectious Disease approved in United States

Frequently asked questions

Is VOQUEZNA® Triple Pak® approved in United States?

Yes. FDA authorised it on 3 May 2022.

Who is the marketing authorisation holder for VOQUEZNA® Triple Pak® in United States?

PHATHOM holds the US marketing authorisation.